Enamine, Lundbeck extend multi-year CNS drug discovery deal

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Olique)
(Image: Getty/Olique)

Related tags: Drug discovery, Lundbeck, Enamine, CNS

Lundbeck extends its research collaboration with the drug discovery services provider Enamine to help “intensify its search for quality lead compounds.”

Lundbeck is a global pharmaceutical company developing drugs for the treatment of central nervous system (CNS) disorders.

The company this week announced that it has expanded its research collaboration with Enamine, as part of which the service provider will support Lundbeck’s in-house discovery chemistry competencies.

For more than 12 years, Lundbeck has been using Enamine's library of screening compounds to support its work. According to the company, Enamine has the world's largest collection of screening compounds, at more than 2.6m, in addition to 170k building blocks.

As part of its work with Enamine, Michael Bossert, head of strategic alliances at Enamine said, “Lundbeck realized the scope of working with Enamine was potentially much greater and they had expertise to deploy a huge chemical space giving access to billions of compounds.”

A more formal collaboration was established in 2017, which gave Lundbeck access to “billions of virtual compounds that could be synthesized within only 3 weeks and with over 80% success rate,"​ Bossert told us.

“This speed and success rate with the further benefit of having 170,000 building blocks, was the basis of this latest phase in the companies' collaboration involving dedicated full-time chemists,”​ he added.

“The announced extension step will help Lundbeck further intensify its search for quality lead compounds that can be used in its research programs.”

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more